Financhill
Sell
40

ADVM Quote, Financials, Valuation and Earnings

Last price:
$2.54
Seasonality move :
-21.58%
Day range:
$2.50 - $2.70
52-week range:
$1.78 - $10.14
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.01x
Volume:
65.8K
Avg. volume:
278.4K
1-year change:
-67.39%
Market cap:
$53.1M
Revenue:
$1M
EPS (TTM):
-$6.40

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ADVM
Adverum Biotechnologies
-- -$2.28 -97.98% -157.58% $19.75
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
VNDA
Vanda Pharmaceuticals
$54.8M -- 8.51% -- $12.67
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ADVM
Adverum Biotechnologies
$2.54 $19.75 $53.1M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.69 $0.85 $4M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.40 -- $22.4M -- $0.00 0% --
OGEN
Oragenics
$1.42 $1.00 $1M -- $0.00 0% 0.45x
TOVX
Theriva Biologics
$0.50 $7.00 $4.1M -- $0.00 0% 0.33x
VNDA
Vanda Pharmaceuticals
$4.99 $12.67 $294.1M -- $0.00 0% 1.45x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ADVM
Adverum Biotechnologies
-- -0.484 -- 5.54x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
NNVC
Nanoviricides
-- -0.318 -- --
OGEN
Oragenics
-- 0.068 -- --
TOVX
Theriva Biologics
-- -3.388 -- --
VNDA
Vanda Pharmaceuticals
-- 0.464 -- 3.71x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ADVM
Adverum Biotechnologies
-- -$48.2M -69.14% -69.14% -2922.1% -$43M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M
VNDA
Vanda Pharmaceuticals
$46.5M -$41M -8.26% -8.26% -81.99% -$33.6M

Adverum Biotechnologies vs. Competitors

  • Which has Higher Returns ADVM or NBY?

    NovaBay Pharmaceuticals has a net margin of -2713.4% compared to Adverum Biotechnologies's net margin of -49.65%. Adverum Biotechnologies's return on equity of -69.14% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ADVM
    Adverum Biotechnologies
    -- -$2.25 $144.1M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About ADVM or NBY?

    Adverum Biotechnologies has a consensus price target of $19.75, signalling upside risk potential of 677.56%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 22.83%. Given that Adverum Biotechnologies has higher upside potential than NovaBay Pharmaceuticals, analysts believe Adverum Biotechnologies is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADVM
    Adverum Biotechnologies
    4 1 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is ADVM or NBY More Risky?

    Adverum Biotechnologies has a beta of 0.701, which suggesting that the stock is 29.914% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock ADVM or NBY?

    Adverum Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADVM or NBY?

    Adverum Biotechnologies quarterly revenues are $1M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Adverum Biotechnologies's net income of -$47M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Adverum Biotechnologies's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADVM
    Adverum Biotechnologies
    -- -- $1M -$47M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns ADVM or NNVC?

    Nanoviricides has a net margin of -2713.4% compared to Adverum Biotechnologies's net margin of --. Adverum Biotechnologies's return on equity of -69.14% beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ADVM
    Adverum Biotechnologies
    -- -$2.25 $144.1M
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About ADVM or NNVC?

    Adverum Biotechnologies has a consensus price target of $19.75, signalling upside risk potential of 677.56%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 365.95%. Given that Adverum Biotechnologies has higher upside potential than Nanoviricides, analysts believe Adverum Biotechnologies is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADVM
    Adverum Biotechnologies
    4 1 0
    NNVC
    Nanoviricides
    0 0 0
  • Is ADVM or NNVC More Risky?

    Adverum Biotechnologies has a beta of 0.701, which suggesting that the stock is 29.914% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.

  • Which is a Better Dividend Stock ADVM or NNVC?

    Adverum Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADVM or NNVC?

    Adverum Biotechnologies quarterly revenues are $1M, which are larger than Nanoviricides quarterly revenues of --. Adverum Biotechnologies's net income of -$47M is lower than Nanoviricides's net income of -$2.2M. Notably, Adverum Biotechnologies's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADVM
    Adverum Biotechnologies
    -- -- $1M -$47M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns ADVM or OGEN?

    Oragenics has a net margin of -2713.4% compared to Adverum Biotechnologies's net margin of --. Adverum Biotechnologies's return on equity of -69.14% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ADVM
    Adverum Biotechnologies
    -- -$2.25 $144.1M
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About ADVM or OGEN?

    Adverum Biotechnologies has a consensus price target of $19.75, signalling upside risk potential of 677.56%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Adverum Biotechnologies, analysts believe Oragenics is more attractive than Adverum Biotechnologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADVM
    Adverum Biotechnologies
    4 1 0
    OGEN
    Oragenics
    0 1 0
  • Is ADVM or OGEN More Risky?

    Adverum Biotechnologies has a beta of 0.701, which suggesting that the stock is 29.914% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock ADVM or OGEN?

    Adverum Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADVM or OGEN?

    Adverum Biotechnologies quarterly revenues are $1M, which are larger than Oragenics quarterly revenues of --. Adverum Biotechnologies's net income of -$47M is lower than Oragenics's net income of -$2.2M. Notably, Adverum Biotechnologies's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies is -- versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADVM
    Adverum Biotechnologies
    -- -- $1M -$47M
    OGEN
    Oragenics
    0.45x -- -- -$2.2M
  • Which has Higher Returns ADVM or TOVX?

    Theriva Biologics has a net margin of -2713.4% compared to Adverum Biotechnologies's net margin of --. Adverum Biotechnologies's return on equity of -69.14% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ADVM
    Adverum Biotechnologies
    -- -$2.25 $144.1M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About ADVM or TOVX?

    Adverum Biotechnologies has a consensus price target of $19.75, signalling upside risk potential of 677.56%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1294.42%. Given that Theriva Biologics has higher upside potential than Adverum Biotechnologies, analysts believe Theriva Biologics is more attractive than Adverum Biotechnologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADVM
    Adverum Biotechnologies
    4 1 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is ADVM or TOVX More Risky?

    Adverum Biotechnologies has a beta of 0.701, which suggesting that the stock is 29.914% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock ADVM or TOVX?

    Adverum Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADVM or TOVX?

    Adverum Biotechnologies quarterly revenues are $1M, which are larger than Theriva Biologics quarterly revenues of --. Adverum Biotechnologies's net income of -$47M is lower than Theriva Biologics's net income of -$4.3M. Notably, Adverum Biotechnologies's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADVM
    Adverum Biotechnologies
    -- -- $1M -$47M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M
  • Which has Higher Returns ADVM or VNDA?

    Vanda Pharmaceuticals has a net margin of -2713.4% compared to Adverum Biotechnologies's net margin of -58.94%. Adverum Biotechnologies's return on equity of -69.14% beat Vanda Pharmaceuticals's return on equity of -8.26%.

    Company Gross Margin Earnings Per Share Invested Capital
    ADVM
    Adverum Biotechnologies
    -- -$2.25 $144.1M
    VNDA
    Vanda Pharmaceuticals
    92.96% -$0.50 $511.4M
  • What do Analysts Say About ADVM or VNDA?

    Adverum Biotechnologies has a consensus price target of $19.75, signalling upside risk potential of 677.56%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 153.84%. Given that Adverum Biotechnologies has higher upside potential than Vanda Pharmaceuticals, analysts believe Adverum Biotechnologies is more attractive than Vanda Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADVM
    Adverum Biotechnologies
    4 1 0
    VNDA
    Vanda Pharmaceuticals
    1 1 0
  • Is ADVM or VNDA More Risky?

    Adverum Biotechnologies has a beta of 0.701, which suggesting that the stock is 29.914% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.683, suggesting its less volatile than the S&P 500 by 31.678%.

  • Which is a Better Dividend Stock ADVM or VNDA?

    Adverum Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adverum Biotechnologies pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADVM or VNDA?

    Adverum Biotechnologies quarterly revenues are $1M, which are smaller than Vanda Pharmaceuticals quarterly revenues of $50M. Adverum Biotechnologies's net income of -$47M is lower than Vanda Pharmaceuticals's net income of -$29.5M. Notably, Adverum Biotechnologies's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adverum Biotechnologies is -- versus 1.45x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADVM
    Adverum Biotechnologies
    -- -- $1M -$47M
    VNDA
    Vanda Pharmaceuticals
    1.45x -- $50M -$29.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock